Prognostic significance of thymidylate synthase polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy
- 27 March 2013
- journal article
- Published by Wiley in Colorectal Disease
- Vol. 15 (4) , 428-435
Abstract
There is a lack of prognostic factors of preoperative chemoradiation for locally advanced rectal cancer. Thymidylate synthase (TS) is the most important target of 5-fluorouracil; three main genetic polymorphisms of TS have been described. We analysed the prognostic value of these in patients with locally advanced rectal cancer treated with fluoropyrimidine-based chemoradiation. Ninety-nine patients treated between November 2001 and March 2009 were included. All were treated by radiotherapy (5040 cGy) and concomitant fluoropyrimidine-based chemotherapy. Three polymorphisms were analysed: (i) a double (2R) or triple (3R) repeat of a 28 base pair (bp) tandem sequence upstream of the ATG codon initiation site in the 5'-terminal regulatory region, (ii) a functional G > C single nucleotide polymorphism present in the second repeat of the 3R alleles and (iii) a 6 bp deletion at nucleotide 1494 in the 3'-untranslated region. DNA was extracted from paraffin-embedded core biopsies taken from the tumour and the genotype was analysed using polymerase chain reaction restriction fragment length polymorphism. The 6 bp polymorphism was significantly associated with disease-free survival (+ 6 bp/+ 6 bp vs-6 bp/-6 bp, P = 0.032 logistic regression). No differences were found in disease-free survival according to the other polymorphisms studied. No relationship was observed between the different TS genotypes and pathological regression. The study suggests that the TS 6 bp polymorphism may be a predictor of disease-free survival in patients with locally advanced rectal cancer treated with fluoropyrimidine-based chemoradiation.Keywords
This publication has 24 references indexed in Scilit:
- Predictive Factors of Complete Response to Neoadjuvant Chemoradiotherapy in Patients with Rectal CancerOncology, 2010
- Thymidylate synthase germline polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy based on 5-fluorouracilJournal of Cancer Research and Clinical Oncology, 2010
- Revised Tumor and Node Categorization for Rectal Cancer Based on Surveillance, Epidemiology, and End Results and Rectal Pooled Analysis OutcomesJournal of Clinical Oncology, 2010
- Molecular analysis of the polymorphisms of thymidylate synthase on cell‐free circulating DNA in blood of patients with advanced colorectal carcinomaInternational Journal of Cancer, 2009
- High Ki67, Bax, and thymidylate synthase expression well correlates with response to chemoradiation therapy in locally advanced rectal cancers: proposal of a logistic model for predictionBritish Journal of Cancer, 2009
- Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapyBritish Journal of Cancer, 2007
- Pathologic response assessed by Mandard grade is a better prognostic factor than down staging for disease‐free survival after preoperative radiochemotherapy for advanced rectal cancerColorectal Disease, 2007
- Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203Journal of Clinical Oncology, 2006
- Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5‐FU‐based neo‐adjuvant chemoradiotherapy in rectal cancerThe Journal of Pathology, 2004
- Thymidylate synthetase - a target enzyme in cancer chemotherapyBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1977